ImmunityBio, Inc.

ImmunityBio, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026. During the meeting, stockholders re-elected nine directors to serve a one-year term expiring at the 2027 annual meeting. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Approximately 85% of the outstanding shares were represented at the meeting.

ImmunityBio entered an exclusive development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strain of Bacillus Calmette-Guerin (BCG) for the U.S. market. This aims to address the decade-long BCG shortage for high-grade non-muscle invasive bladder cancer (NMIBC) patients. The agreement grants ImmunityBio exclusive U.S. rights for 10 years post-FDA approval, with no upfront payments. The Tokyo strain demonstrated non-inferior efficacy to TICE BCG in the NCI-sponsored SWOG S1602 Phase III trial, with a 5-year high-grade recurrence-free survival of 64% for Tokyo vs. 58% for TICE. This provides ImmunityBio a second potential BCG source, alongside its existing rBCG partnership.

ImmunityBio reported a significant increase in total revenue for Q1 2026, reaching $44.2 million, primarily driven by U.S. sales of ANKTIVA. However, the company's net loss widened substantially to $(632.8) million, largely due to significant non-cash expenses from changes in the fair value of warrant liabilities and a related-party convertible note. The company also raised $223.9 million through financing activities, including equity offerings and proceeds from the RIPA, but noted substantial doubt about its ability to continue as a going concern without additional funding.

ImmunityBio reported record first-quarter 2026 financial results, with net product revenue increasing 168% year-over-year to $44.2 million, driven by strong ANKTIVA sales momentum. The company ended the quarter with a robust cash position of $380.9 million. Operational highlights include ANKTIVA's expanded regulatory approvals across 34 countries, full enrollment of its pivotal BCG-naïve NMIBC trial, and updated NCCN guideline recommendations for ANKTIVA plus BCG. While the GAAP net loss was $632.8 million, this was largely due to non-cash fair value changes related to an increase in common stock price.

ImmunityBio, Inc. reported a transformational year in 2025 and early 2026, driven by the commercial success of ANKTIVA®. The company achieved approximately $113 million in net product revenue for ANKTIVA® in 2025, a 700% increase year-over-year, following its April 2024 FDA approval. Global expansion continued with approvals in the UK and EU, and a significant accelerated approval in China for metastatic non-small cell lung cancer. The company also announced its Annual Meeting of Stockholders for June 9, 2026, to elect directors and ratify auditors.

ImmunityBio, Inc. announced preliminary, unaudited financial results for the fiscal quarter ended March 31, 2026, along with additional company updates. These results are based on preliminary estimates available as of April 9, 2026, and are not a comprehensive statement of the company's operating results or financial position. Investors should note that the actual amounts reported in the upcoming Form 10-Q may differ materially from these preliminary estimates due to standard financial closing procedures and potential final adjustments. The announcement provides an early look at the company's performance, though specific figures were not detailed in the filing.

ImmunityBio submitted a comprehensive response to a Warning Letter issued by the FDA concerning the promotion of its prescription drugs. The company outlined immediate and planned corrective actions, indicating a regulatory challenge and potential impact on its marketing practices.